{
    "ticker": "INMB",
    "name": "InMed Pharmaceuticals Inc.",
    "description": "InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for the treatment of diseases associated with the endocannabinoid system. Founded in 2010 and based in Vancouver, Canada, InMed is focused on leveraging its proprietary biosynthesis platform to create cannabinoid-based therapies that address significant unmet medical needs. The company is advancing a robust pipeline of drug candidates, including INM-755 for the treatment of epidermolysis bullosa and INM-088 for neurodegenerative diseases. InMed's innovative approach combines advanced drug development with a deep understanding of cannabinoid pharmacology, aiming to provide safe and effective treatments that improve patients' quality of life. The company is committed to rigorous scientific research and collaboration with leading medical institutions to validate its therapies through clinical trials. InMed's vision is to harness the potential of cannabinoids to redefine therapeutic approaches for a variety of health conditions, positioning itself as a leader in the dynamic biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "2010",
    "website": "https://www.inmedpharma.com",
    "ceo": "Eric A. Adams",
    "social_media": {
        "twitter": "https://twitter.com/InMedPharma",
        "linkedin": "https://www.linkedin.com/company/inmed-pharmaceuticals/"
    },
    "investor_relations": "https://investors.inmedpharma.com",
    "key_executives": [
        {
            "name": "Eric A. Adams",
            "position": "CEO"
        },
        {
            "name": "Andrew M. Y. S. K. A. H. S. H. D. H. H. H. H.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "INM-755",
                "INM-088"
            ]
        }
    ],
    "seo": {
        "meta_title": "InMed Pharmaceuticals Inc. | Pioneering Cannabinoid-Based Therapies",
        "meta_description": "Explore InMed Pharmaceuticals Inc., a leader in cannabinoid-based drug development. Learn about their innovative therapies and commitment to improving patient outcomes.",
        "keywords": [
            "InMed Pharmaceuticals",
            "Cannabinoid Therapies",
            "Biopharmaceuticals",
            "Clinical Trials",
            "Epidermolysis Bullosa"
        ]
    },
    "faq": [
        {
            "question": "What does InMed Pharmaceuticals specialize in?",
            "answer": "InMed Pharmaceuticals specializes in cannabinoid-based therapies for various health conditions."
        },
        {
            "question": "Who is the CEO of InMed Pharmaceuticals?",
            "answer": "Eric A. Adams is the CEO of InMed Pharmaceuticals Inc."
        },
        {
            "question": "Where is InMed Pharmaceuticals headquartered?",
            "answer": "InMed Pharmaceuticals is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are InMed's main drug candidates?",
            "answer": "InMed's main drug candidates include INM-755 for epidermolysis bullosa and INM-088 for neurodegenerative diseases."
        },
        {
            "question": "When was InMed Pharmaceuticals founded?",
            "answer": "InMed Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "TLRY"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "VRTX"
    ]
}